Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial
2015; American Association for Cancer Research; Volume: 21; Issue: 9 Linguagem: Inglês
10.1158/1078-0432.ccr-15-0426
ISSN1557-3265
AutoresLorraine A. Chantrill, Adnan Nagrial, Clare Watson, Amber L. Johns, Mona Martyn-Smith, Skye H. Simpson, Scott Mead, Marc D. Jones, Jaswinder S. Samra, Anthony J. Gill, Nicole Watson, Venessa Chin, Jeremy L. Humphris, Angela Chou, Belinda Brown, Adrienne Morey, Marina Pajic, Sean M. Grimmond, David K. Chang, David M. Thomas, Lucille Sebastian, Katrin Marie Sjoquist, Sonia Yip, Nick Pavlakis, Ray Asghari, Sandra Harvey, Peter Grimison, John Simes, Andrew V. Biankin,
Tópico(s)Renal cell carcinoma treatment
ResumoPersonalized medicine strategies using genomic profiling are particularly pertinent for pancreas cancer. The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) trial was initially designed to exploit results from genome sequencing of pancreatic cancer under the auspices of the International Cancer Genome Consortium (ICGC) in Australia. Sequencing revealed small subsets of patients with aberrations in their tumor genome that could be targeted with currently available therapies.
Referência(s)